News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products
Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, ten scientific presentations with data focused on Melinta’s portfolio of commercial and investigational stage products to be shared at Infectious Disease Week (IDWeek) 2024, Oct. 16-19, 2024, in Los Angeles, Californi
Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer
Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Sunitha Lakshminarayanan, as Chief Technology Officer, effective today.
Melinta Therapeutics Announces the Appointment of Fabrizio Tondolo, MD, as Vice President of Medical Affairs
August 6, 2024Press ReleaseParsippany, N.J. – August 6, 2024 – Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening...
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
May 23, 2024Press ReleasePublication reaffirms the efficacy of rezafungin for treatment of candidemia and invasive candidiasis (IC) in adult patients across Candida species PARSIPPANY, NJ—May 23,...